Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity (Q37558534)

21 August 2017

1 reference

title

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity (English)

1 reference

21 August 2017

1 reference

1 reference

William Kells Boland

1

1 reference

PubMed ID

19624281

21 August 2017

Gwyn Bebb

series ordinal

2

1 reference

PubMed ID

19624281

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Biological Therapy

21 August 2017

1 reference

21 August 2017

9

1 reference

21 August 2017

9

1 reference

21 August 2017

1199-1206

1 reference

Signaling through the epidermal growth factor receptor during the development of malignancy

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Tumor invasion as dysregulated cell motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Cetuximab, its clinical use and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Ethics in oncology: consulting for the investment industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Palliative thoracic radiotherapy for lung cancer: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem-cell transplantation: is the evidence clear?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903110709

10.1517/14712590903110709

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19624281